Can Vraylar Cause Tremor?
Yes, Vraylar (cariprazine) can cause tremor—it is explicitly listed as one of the most common side effects in the FDA drug label and occurs at approximately twice the rate of placebo in clinical trials. 1
Evidence from FDA Drug Label
The FDA-approved prescribing information for Vraylar clearly identifies tremor as a common adverse effect. Specifically:
- Tremor is listed among the most common side effects alongside "difficulty moving or slow movements, uncontrolled body movements, restlessness and feeling like you need to move around" 1
- These extrapyramidal symptoms (EPS) are part of the expected side effect profile for this medication
- The drug label emphasizes that side effects may not appear immediately and can emerge weeks after starting treatment or after dose increases, as Vraylar has a long half-life 1
Clinical Trial Data
Research evidence confirms the FDA labeling findings:
- In a 2016 meta-analysis of phase II/III randomized controlled trials, cariprazine was associated with significantly higher risk of tremor compared to placebo (RR 2.41,95% CI 1.53-3.79) 2
- A 2015 bipolar disorder trial identified tremor as one of the most common treatment-emergent adverse events, occurring in ≥10% of patients at twice the placebo rate 3
- A 2025 pooled analysis of major depressive disorder trials found that while akathisia, nausea, and insomnia were the most frequent EPS-related effects, tremor remained part of the overall extrapyramidal symptom profile 4
Clinical Context and Management
Tremor from Vraylar is part of the broader category of extrapyramidal side effects (EPS), which are well-documented with antipsychotic medications. The mechanism relates to dopamine D2/D3 receptor activity in the basal ganglia 5.
Key Clinical Considerations:
- Dose relationship: EPS-related effects, including tremor, may show dose-dependent patterns, though tremor specifically occurs across the therapeutic dose range 2, 3
- Time course: Due to Vraylar's long half-life and active metabolites, tremor may emerge or persist for several weeks after starting or adjusting the medication 1
- Monitoring: Healthcare providers should monitor for EPS symptoms for several weeks after initiation or dose increases 1
Common Pitfall to Avoid:
Do not confuse drug-induced tremor with worsening of underlying psychiatric symptoms or assume it will resolve quickly—Vraylar's pharmacokinetics mean effects persist longer than with shorter-acting antipsychotics 1.
Comparison to Other Antipsychotics
While cariprazine does cause tremor, the overall metabolic profile appears more favorable than some other atypical antipsychotics. The 2016 meta-analysis found that EPS-related adverse events were the main short-term concern, but metabolic parameters and cardiovascular effects showed no statistically significant differences from placebo 2. This distinguishes it from agents like olanzapine or clozapine, which carry higher metabolic risks but may have different EPS profiles 6.
In summary: Tremor is a recognized and relatively common adverse effect of Vraylar that clinicians should anticipate, monitor for, and discuss with patients before initiating treatment.